Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03056001 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT03056001 is a Phase 2 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 30 participants.
The verdict
NCT03056001, a Phase 2 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of doxorubicin in combination with pembrolizumab in subjects with metastatic or unresectable soft tissue sarcoma. Based on previous studies, pembrolizumab may be an effective study treatment.
Interventions
- DRUG Pembrolizumab
- DRUG Doxorubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-05-01 |
| Est. Completion | 2022-11-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03056001
The ClinicalTrials.gov registry entry for NCT03056001 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03056001 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03056001 about?
NCT03056001 is a clinical study titled "Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma". The purpose of this study is to evaluate the safety, tolerability and efficacy of doxorubicin in combination with pembrolizumab in subjects with metastatic or unresectable soft tissue sarcoma. Based on previous studies, pembrolizumab may be an effective study treatment.
What is the current status of trial NCT03056001?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2017-05-01. Estimated completion is 2022-11-15.
What interventions are being tested in trial NCT03056001?
The interventions under investigation include: Pembrolizumab (DRUG), Doxorubicin (DRUG).
Who is sponsoring clinical trial NCT03056001?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.